Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12183
Abstract: Cancer immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized oncology. However, only a limited number of patients benefit from immunotherapy, and some cancers that initially respond to immunotherapy can ultimately relapse and progress. Thus, some… read more here.
Keywords: immunity; cancer immunotherapy; antiangiogenic agents; cancer ... See more keywords
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Seminars in liver disease"
DOI: 10.1055/s-0038-1673621
Abstract: Multikinase inhibitors with antiangiogenic properties used to be standard therapy for patients with advanced hepatocellular carcinoma (HCC). Recently, several antiangiogenic agents (lenvatinib, cabozantinib, and ramucirumab) have demonstrated antitumor activity for advanced HCC in randomized controlled… read more here.
Keywords: hepatocellular carcinoma; combination; carcinoma; multikinase inhibitors ... See more keywords
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1325871
Abstract: ABSTRACT Introduction: Recurrence is a common event in endothelial ovarian cancer (EOC) patients, and the choice of the most appropriate treatment is driven by the platinum-free interval, molecular characteristics of the disease such as BRCA… read more here.
Keywords: parp inhibitors; agents parp; ovarian cancer; antiangiogenic agents ... See more keywords
The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis: Erratum
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000007230
Abstract: [This corrects the article DOI: 10.1097/MD.0000000000006301.]. read more here.
Keywords: role antiangiogenic; treatment gastric; gastric cancer; antiangiogenic agents ... See more keywords
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14603
Abstract: Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. read more here.
Keywords: cancer; non small; agents non; small cell ... See more keywords
Hypothyroidism induced by immune checkpoint inhibitors combined with antiangiogenic agents is associated with higher body mass index
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-23-306
Abstract: Background Recent studies have reported that the combination of immune checkpoint inhibitors (ICIs) and antiangiogenic agents could be a promising therapeutic strategy for advanced non-small cell lung cancer (NSCLC). However, both ICIs and antiangiogenic agents… read more here.
Keywords: immune checkpoint; combination; antiangiogenic agents; icis antiangiogenic ... See more keywords